ARGX argenx NV ADR

USD 358.41 -7.79 -2.127253
Icon

argenx NV ADR (ARGX) Stock Analysis and Price Targets

COMMON STOCK | Biotechnology | NSD
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Neutral

Stock Target Advisor
Analysis
stockTargetAdvisor

Buy

Average User
Rating

USD 358.41

-7.79 (-2.13)%

USD 21.60B

0.24M

USD 501.87(+40.03%)

USD 525.00 (+46.48%)

Icon

ARGX

argenx NV ADR (USD)
COMMON STOCK | NSD
USD 358.41
0.00 0
Take a Tour
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Neutral

Stock Target Advisor
Analysis
stockTargetAdvisor

Buy

Average User
Rating

USD 21.60B

USD 525.00 (+46.48%)

USD 358.41

argenx NV ADR (ARGX) Stock Forecast

Show ratings and price targets of :
USD 501.87
(+40.03%)

Based on the argenx NV ADR stock forecast from 12 analysts, the average analyst target price for argenx NV ADR is USD 501.87 over the next 12 months. argenx NV ADR’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of argenx NV ADR is Neutral, which is based on 4 positive signals and 4 negative signals. At the last closing, argenx NV ADR’s stock price was USD 358.41. argenx NV ADR’s stock price has changed by -5.59% over the past week, -0.87% over the past month and -4.62% over the last year.

No recent analyst target price found for argenx NV ADR
No recent average analyst rating found for argenx NV ADR

Company Overview argenx NV ADR

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myastheni...Read More

https://www.argenx.com

Willemstraat 5, Breda, Netherlands, 4811 AH

1,148

December

USD

USA

Adjusted Closing Price for argenx NV ADR (ARGX)

Loading...

Unadjusted Closing Price for argenx NV ADR (ARGX)

Loading...

Share Trading Volume for argenx NV ADR Shares

Loading...

Compare Performance of argenx NV ADR Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for ARGX

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To argenx NV ADR (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX
Vertex Pharmaceuticals Inc +0.38 (+0.10%) USD107.38B 29.93 21.06

ETFs Containing ARGX

Symbol Name ARGX's Weight Expense Ratio Price(Change) Market Cap
TEET:LSE
VanEck Sustainable Europe.. 1.08 % 0.20 % +0.49 (+0.64%) USD0.05B

Frequently Asked Questions About argenx NV ADR (ARGX) Stock

Based on ratings from 12 analysts argenx NV ADR's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Neutral. The stock has 22 buy, sell and 1 hold ratings.

Unfortunately we do not have enough data on ARGX's stock to indicate if its a good dividend stock.

Based on targets from 12 analysts, the average taret price for ARGX is USD 501.87 over the next 12 months. The maximum analyst target price is USD 607 while the minimum anlayst target price is USD 402.

Unfortunately we do not have enough data on ARGX's stock to indicate if its overvalued.

The last closing price of ARGX's stock was USD 358.41.

The most recent market capitalization for ARGX is USD 21.60B.

Based on targets from 12 analysts, the average taret price for ARGX is projected at USD 501.87 over the next 12 months. This means that ARGX's stock price may go up by +40.03% over the next 12 months.

Following are ETFs with the highest allocation to argenx NV ADR's stock :

TEET:LSE

As per our most recent records argenx NV ADR has 1,148 Employees.

argenx NV ADR's registered address is Willemstraat 5, Breda, Netherlands, 4811 AH. You can get more information about it from argenx NV ADR's website at https://www.argenx.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...